

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



TransThera Sciences (Nanjing), Inc.
藥捷安康(南京)科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2617)

PROPOSED ADOPTION OF THE H SHARE AWARD SCHEME

PROPOSED ADOPTION OF THE H SHARE AWARD SCHEME

The Board has resolved to propose the adoption of the H Share Award Scheme at the Board meeting held on April 7, 2026. The grant of Awards shall be satisfied by the treasury shares or the new H Shares (collectively “**New Shares**”) issued by the Company, or existing H Shares.

The H Share Award Scheme becoming effective is conditional upon:

- (i) the passing of a special resolution by the Shareholders to approve the adoption of the Scheme; and
- (ii) the Listing Committee granting approval of the listing of, and permission to deal in, the Shares to be allotted and issued pursuant to Awards.

Pursuant to Chapter 17 of the Listing Rules, the H Share Award Scheme will constitute a share scheme of the Company involving the issue of new Shares and therefore the adoption of the H Share Award Scheme is subject to the approval of the Shareholders.

PROPOSED AUTHORIZATION TO THE SCHEME ADMINISTRATOR TO DEAL WITH MATTERS RELATING TO THE H SHARE AWARD SCHEME

In order to implement the H Share Award Scheme, pursuant to the provisions of the relevant laws, regulations and regulatory documents such as the Listing Rules and the Articles of Association of the Company, the Board has proposed that, subject to the approval of the H Share Award Scheme by the Shareholders at the forthcoming extraordinary general meeting of the Company, the Shareholders also grant an authorization to the Scheme Administrator to take all relevant measures and deal with all relevant matters to approve and execute on behalf of the Company such documents as are necessary, appropriate or expedient for the purpose of giving effect and implementation of the H Share Award Scheme and to handle matters relating to the H Share Award Scheme.

EGM

The Company will convene an extraordinary general meeting to seek Shareholders' approval for, among other things, the adoption of the H Share Award Scheme and related matters. A circular containing, among other things, a notice of the EGM and details of the proposed adoption of the H Share Award Scheme and related matters, will be published in due course.

As at the date of this announcement, the proposed adoption of the H Share Award Scheme is subject to the approval of the Shareholders. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Company's securities.

DEFINITIONS

In this announcement, the following words and expressions shall, unless the context otherwise requires, have the following respective meanings:

“Award”	an award granted under the Scheme by the Scheme Administrator to a Grantee, which may take the form of a Share Option or a Share Award, and which shall be funded by Award Shares
“Award Share(s)”	Shares underlying an Award, and includes newly allotted and issued Shares for the purpose of implementation of the Scheme at nil consideration or otherwise
“Board”	the board of directors of the Company
“Company”	TransThera Sciences (Nanjing), Inc. (藥捷安康(南京)科技股份有限公司), a joint stock company incorporated in the People's Republic of China with limited liability whose H Shares are listed on the Hong Kong Stock Exchange (Stock Code: 2617)
“EGM”	extraordinary general meeting of the Company to be convened and held for the purpose of considering and, if thought fit, approving, among others, the adoption of the H Share Award Scheme
“Eligible Participant(s)”	an employee participant, related entity participant or service provider participant, as defined in the Scheme Rules

“Grantee”	any Eligible Participant approved for participation in the Scheme and who has been granted any Award
“Group”	the Company and its subsidiaries, and the expression “member of the Group” shall be construed accordingly
“H Shares”	overseas listed foreign shares with a nominal value of RMB1.00 each in the share capital of the Company, which are listed on the Stock Exchange
“H Share Award Scheme” or “Scheme”	the “2026 H Share Award Scheme” to be adopted by the Company as proposed by the resolution of the Board passed on April 7, 2026
“Hong Kong”	the Hong Kong Special Administrative Region of the People’s Republic of China
“Listing Committee”	the Listing Committee of the Stock Exchange
“Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited
“PRC”	the People’s Republic of China (for the purpose of this announcement only, excluding Hong Kong, the Macau Special Administrative Region of the PRC and Taiwan)
“Scheme Administrator”	the Board and/or any committee of the Board or other person to whom the Board has delegated its authority in accordance with the Scheme Rule
“Scheme Rules”	relevant rules of the H Share Award Scheme
“Share(s)”	shares with a par value of RMB1.00 each in the share capital of the Company, or, if there has been a subdivision, consolidation, re-classification or reconstruction of the share capital of the Company, shares forming part of the ordinary share capital of the Company of such other nominal amount as shall result from such sub-division, consolidation, re-classification or reconstruction

“Share Award”	an award which vests in the form of the right to subscribe for and/or to be issued such number of H Award Shares as the Scheme Administrator may determine at the purchase in accordance with the terms of the Scheme Rules
“Share Option”	an award which vests in the form of the right to subscribe for such number of H Award Shares as the Scheme Administrator may determine during the Exercise Period at the Exercise Price in accordance with the terms of the Scheme Rules
“Shareholder(s)”	holders of Shares

By order of the Board
TransThera Sciences (Nanjing), Inc.
藥捷安康(南京)科技股份有限公司
Dr. Frank Wu
Chairman and Chief Executive Officer

Hong Kong, April 7, 2026

As at the date of this announcement, the Board comprises: (i) Dr. Frank Wu and Mr. Wu Di as executive directors; (ii) Ms. Jia Zhongxin as a non-executive director; and (iii) Mr. Li Shu Pai, Ms. Chui Hoi Yam and Ms. Zheng Zhelan as independent non-executive directors.